Table 3.

Statistical comparison of DFN-15 oral solution and celecoxib 400-mg oral capsules

Parameter	Geometric LSMsa				Comparison (mg)	Ratio (%)	90% CIs	Intrasubject CV (%)
	DFN-15 120 mg (n  =  15)b	DFN-15 180 mg (n  =  15)b	DFN-15 240 mg (n  =  15)b	Oral capsules 400 mg (n  =  15)b
C max	1041.4	1512.5	1899.0	565.9	120 vs. 400	184.0	159.4–212.4	23.6
					180 vs. 400	267.3	231.5–308.5
					240 vs. 400	335.6	290.7–387.4
AUC0–2h c	1291.4	1920.1	2558.5	433.2	120 vs. 400	298.1	245.7–361.7	32.1
					180 vs. 400	443.2	365.3–537.8
					240 vs. 400	590.6	486.8–716.6
${\text{AUC}}_{0-\text{Re f}{T}_{\text{max}}}$	1530.4	2264.3	3071.6	680.2	120 vs. 400	225.0	191.0–265.0	27.0
					180 vs. 400	332.9	282.6–392.1
					240 vs. 400	451.6	383.4–531.9
AUC0–T	2890.1	4385.0	6137.1	6789.6	120 vs. 400	42.6	39.3–46.2	13.2
					180 vs. 400	64.6	59.6–70.0
					240 vs. 400	90.4	83.4–98.0
AUC0–∞	3254.9	4977.2	6763.2	7783.8	120 vs. 400	41.8	38.6–45.3	11.5
					180 vs. 400	63.9	59.1–69.3
					240 vs. 400	86.9	80.2–94.1

AUC area under the plasma concentration–time curve, ${\text{AUC}}_{0-\text{Re f}{T}_{\text{max}}}$ AUC from baseline through T _max, AUC _0–T AUC from baseline through the last measured concentration, AUC _0–2h AUC from baseline through 2 h post-dose, AUC _0–∞ AUC extrapolated to infinity, AUC _0–T/∞ AUC_0–T with respect to AUC_0–∞, CI confidence interval, C _max maximum observed plasma concentration, CV coefficient of variation, LSM least-square means, T _max time to peak concentration, t _½ terminal half-life, λ _Z apparent elimination rate constant

^aValues are ng/ml for C _max and ng·h/mL for AUCs

^b n  =  11 for λ_Z, AUC_0–∞, AUC_0–T/∞, and t_½

^c n  =  12 for DFN-15 120 mg, n  =  14 for DFN-15 180 mg, n  =  12 for DFN-15 240 mg, and n  =  14 for celecoxib 400-mg oral capsules